omeprazole has been researched along with Parkinson Disease in 2 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bjarnason, IT | 2 |
| Charlett, A | 1 |
| Dobbs, RJ | 1 |
| Dobbs, SM | 1 |
| Ibrahim, MA | 1 |
| Kerwin, RW | 1 |
| Mahler, RF | 1 |
| Oxlade, NL | 1 |
| Peterson, DW | 1 |
| Plant, JM | 1 |
| Price, AB | 1 |
| Weller, C | 1 |
| Pierantozzi, M | 1 |
| Pietroiusti, A | 1 |
| Galante, A | 1 |
| Sancesario, G | 1 |
| Lunardi, G | 1 |
| Fedele, E | 1 |
| Giacomini, P | 1 |
| Stanzione, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Helicobacter Pylori Eradication and Motor Fluctuations in Parkinson's Disease[NCT00664209] | Phase 3 | 64 participants (Actual) | Interventional | 2008-01-31 | Terminated (stopped due to Prevalence of H Pylori in the study population was much lower than anticipated) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Side effects profile (NCT00664209)
Timeframe: 2 months
| Intervention | participants (Number) |
|---|---|
| Active | 0 |
2 trials available for omeprazole and Parkinson Disease
| Article | Year |
|---|---|
Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-b
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Clarithromycin; Double-Blind | 2005 |
Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients.
Topics: Administration, Oral; Aged; Analysis of Variance; Anti-Bacterial Agents; Anti-Ulcer Agents; Area Und | 2001 |